Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced it will present new two-year clinical data for CRENESSITY (crinecerfont) at the Endocrine Society's annual meeting ENDO 2026, taking place June 13-16 in Chicago.

The presentations will include analyses spanning adult and pediatric populations with classic congenital adrenal hyperplasia (CAH). The data will cover longer-term clinical outcomes related to androgen control, glucocorticoid dose reduction, metabolic health, bone health, growth and development, and patient-reported quality of life measures.

Neurocrine will present 13 abstracts covering CRENESSITY data from the CAHtalyst clinical program's long-term extension studies. The presentations include both oral presentations and poster sessions scheduled throughout the conference.

The company will also present a case series examining the use of CRENESSITY in patients with classic CAH due to 11β-hydroxylase deficiency, which represents approximately 5% of all classic CAH cases.

Additionally, Neurocrine will present data on VYKAT XR (diazoxide choline) extended-release tablets for hyperphagia associated with Prader-Willi syndrome, including late-breaking findings from a randomized withdrawal study and three-year efficacy data.

CRENESSITY is an oral corticotropin-releasing factor type 1 receptor antagonist approved by the FDA in December 2024 for treating classic CAH in adults and children aged 4 years and older. The drug is used together with glucocorticoids to control androgen levels.

The CAHtalyst studies represented the largest clinical trial program in classic CAH, including 285 pediatric and adult patients across two Phase 3 studies that supported FDA approval.